Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement factor Bb is a serine protease fragment derived from complement factor B. It is a key component of the alternative pathway C3 and C5 convertases, playing a central role in amplifying the complement cascade and mediating immune responses. Bb is generated upon cleavage of factor B by factor D when factor B is bound to C3b. As a catalytic subunit, Bb is essential for cleaving C3 and C5, leading to opsonization, inflammation, and cell lysis. Elevated levels of Bb can serve as a biomarker for diseases involving dysregulated complement activity.
Bb is a catalytic subunit of the C3 and C5 convertases, which cleave C3 and C5, respectively, leading to downstream complement activation. Therapeutic strategies may aim to inhibit its activity or formation to dampen excessive complement activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement Factor Bb (Bb).